Wednesday, July 9, 2014

Fwd: CDER New July 9, 2014



---------- Forwarded message ----------
From: U.S. Food & Drug Administration (FDA) <fda@service.govdelivery.com>
Date: Wed, Jul 9, 2014 at 8:00 AM
Subject: CDER New July 9, 2014
To: iammejtm@gmail.com


FDA (U.S. Food and Drug Administration)

What's New on the FDA Drugs Site

July 8, 2014


New and Generic Drug Approvals

July 7, 2014

Drug NameActive Ingredient Dosage Form/RouteSponsor Submission Type
Desvenlafaxine desvenlafaxine Tablet, Extended Release;Oral Alembic Pharms Ltd Labeling Revision
Effexor Xr venlafaxine hydrochloride Capsule, Extended Release;Oral Wyeth Pharms Inc Labeling Revision
Indium In-111 Oxyquinoline indium in-111 oxyquinoline Injectable;Injection Ge Healthcare Manufacturing Change or Addition
Kerydin tavaborole Solution;Topical Anacor Pharms Inc Approval
Marqibo Kit vincristine sulfate Injectable, Liposomal;Intravenous Talon Therap Manufacturing Change or Addition
Telmisartan telmisartan Tablet; Oral Glenmark Generics Approval
Telmisartan telmisartan Tablet; Oral Alembic Ltd Approval
Telmisartan telmisartan Tablet;Oral Mylan Pharms Inc Approval
Telmisartan telmisartan Tablet;Oral Torrent Pharms Approval

 


FDA Logo

Subscriber Services:
Manage Preferences  |  Unsubscribe  |  Help with this service

Stay Connected:
Visit Us on Facebook Visit Us on Twitter Visit Us on YouTube Sign up for email updates Visit Us on Flickr Visit Our Blog  

This email was sent to iammejtm@gmail.com using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420 Powered by GovDelivery



--
Jeremy Tobias Matthews

No comments:

Post a Comment